ALX Oncology
ALXO
99 hedge funds and large institutions have $349M invested in ALX Oncology in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 32 reducing their positions, and 16 closing their positions.
20% more capital invested
Capital invested by funds: $291M → $349M (+$58M)
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
2% more funds holding
Funds holding: 97 → 99 (+2)
1.1% more ownership
Funds ownership: 88.33% → 89.42% (+1.1%)
19% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 32
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.5M |
| 2 |
O
OrbiMed
New York
|
+$7.98M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.51M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.46M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.6M |
| 2 |
Millennium Management
New York
|
-$2.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.92M |
| 4 |
Two Sigma Investments
New York
|
-$1.61M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.51M |
ALXO Hedge Fund Activity: Q3 2022 in Review
99 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2022, worth a combined $349M — up 20% from $291M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALXO positions and 16 closed out — a net gain of 2 holders — while 26 added to existing stakes and 32 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $10.5M. The largest seller was Wellington Management Group, cutting an estimated $12.6M.
- 99 institutional investors held ALX Oncology (ALXO) as of Q3 2022, up from 97 in Q2 2022.
- Funds reported $349M of ALX Oncology stock for Q3 2022, up 20% quarter-over-quarter.
- 18 funds opened new ALX Oncology positions in Q3 2022 and 16 closed out, a net change of +2 holders.
- The largest ALX Oncology buyer in Q3 2022 was Eventide Asset Management, an estimated $10.5M added.
- The largest ALX Oncology seller in Q3 2022 was Wellington Management Group, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2022.